Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (NASDAQ: BIVI) generates news primarily through its clinical development programs in neurological and neurodegenerative disorders and advanced liver disease. Company announcements frequently highlight progress with its lead candidate bezisterim (NE3107) in Alzheimer’s disease, Parkinson’s disease and long COVID, as well as developments in its BIV201 program for complications of advanced liver cirrhosis.
Recent news releases have described milestones in the SUNRISE-PD Phase 2 trial in early Parkinson’s disease, including the use of a hybrid, decentralized design that allows participants to complete visits at home or in clinics, and the completion of enrollment in that study. BioVie also issues updates on scientific presentations at international conferences, where it has discussed bezisterim’s potential effects on biological aging markers, DNA methylation patterns, inflammatory gene expression, and metabolic and inflammatory biomarkers in Alzheimer’s disease.
In long COVID, BioVie’s news flow includes coverage of the ADDRESS-LC Phase 2 trial, which is enrolling adults with fatigue and cognitive impairment associated with long COVID and is fully funded by a U.S. Department of Defense grant. Press releases describe the trial’s enrichment strategy, objective cognitive endpoints, and the rationale for targeting neuroinflammation and insulin resistance in this condition.
BioVie also reports on capital markets and corporate events, such as underwritten public offerings of units consisting of common stock (or pre-funded warrants) and warrants, the listing of its warrants under the symbol BIVIW, and investor webinars featuring management discussing clinical data and program updates. Regulatory and governance news, including reverse stock split implementation, proxy statements, and board appointments, is disclosed through SEC filings and related communications.
Investors and observers following BIVI news can expect updates on clinical trial enrollment and topline data timing, scientific presentations, financing transactions, and corporate governance actions, all of which are documented in the company’s press releases and regulatory filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioVie Inc. (NASDAQ: BIVI) announced that a data abstract from its Phase 2 open-label trial of NE3107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry in San Diego from April 27-29, 2023. The study titled Effects of NE3107 on Depression and Multimodal Outcomes in a Phase 2, Open-Label Study in Patients with Cognitive Decline Due to Degenerative Dementias will be presented by Nily Osman, MD. NE3107 is designed to inhibit inflammatory activation linked to neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company is also conducting a pivotal Phase 3 study to evaluate NE3107 in Alzheimer's patients. Additionally, BIV201, a continuous infusion terlipressin, is being assessed in a Phase 2b study for refractory ascites due to liver cirrhosis.
BioVie, a clinical-stage company focused on innovative drug therapies for neurological disorders, announced data from its Phase 2 trials of NE3107 for degenerative dementias and Parkinson’s Disease. These abstracts will be presented at the 2023 American Academy of Neurology Annual Meeting, taking place April 22-27, 2023. Notable presentations include:
- Multi-Modal Correlation Analyses: April 25, 8:00-9:00 am ET
- Clinical Outcomes Study: April 25, 11:45 am-12:45 pm ET
- Safety and Efficacy Study: April 23, 8:00-9:00 am ET
BioVie is also advancing its Phase 3 study of NE3107 in Alzheimer’s patients and conducting a Phase 2b study for its liver disease treatment, BIV201. The latter has received FDA Fast Track designation.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
